Efficacy and safety of epidermal growth factor receptor-tyrosine kinase inhibitor (EGFR-TKI) monotherapy for advanced EGFR-mutated non-small cell lung cancer …
It is controversial whether there is efficacy or safety benefit of epidermal growth factor
receptor-tyrosine kinase inhibitor (EGFR-TKI) in advanced EGFR-mutated non-small cell …
receptor-tyrosine kinase inhibitor (EGFR-TKI) in advanced EGFR-mutated non-small cell …
[PDF][PDF] 特罗凯靶向治疗联合培美曲塞和顺铂对非小细胞肺癌患者血清肿瘤标志物, 免疫球蛋白和T 淋巴细胞亚群的影响
许英， 杨洁， 李娜， 安晓娟， 黄兵， 张霞 - 现代生物医学进展, 2021 - biomed.cnjournals.com
摘要目的: 探讨特罗凯靶向治疗联合培美曲塞和顺铂对非小细胞肺癌(NSCLC)
患者血清肿瘤标志物, 免疫球蛋白和T 淋巴细胞亚群的影响. 方法: 选取2018 年2 月~ 2020 年2 …
患者血清肿瘤标志物, 免疫球蛋白和T 淋巴细胞亚群的影响. 方法: 选取2018 年2 月~ 2020 年2 …
[HTML][HTML] Shared network pattern of lung squamous carcinoma and adenocarcinoma illuminates therapeutic targets for non-small cell lung cancer
P Li, X Kuang, T Zhang, L Ma - Frontiers in Surgery, 2022 - frontiersin.org
Background: Non-small cell lung cancer is considered to be one of the malignant tumors
with high mortality. However, the prognosis of its advanced patients is still poor. This study …
with high mortality. However, the prognosis of its advanced patients is still poor. This study …
[HTML][HTML] Second and later-line erlotinib use in non-small cell lung cancer: real world outcomes and practice patterns overtime in Canada
K Perdrizet, R Sutradhar, Q Li, N Liu… - Journal of Thoracic …, 2021 - ncbi.nlm.nih.gov
Background In Canada, epidermal growth factor receptor (EGFR) inhibitor therapies in
advanced non-small cell lung cancer (NSCLC) were initially approved regardless of EGFR …
advanced non-small cell lung cancer (NSCLC) were initially approved regardless of EGFR …